One Endothelium-Targeted Combined Nucleic Acid Delivery System for Myocardial Infarction Therapy

Area of Science:

• Biomedical Engineering
• Cardiovascular Research
• Gene Therapy

Background:

• Acute myocardial infarction (MI) is a primary cause of heart failure and mortality.
• Current MI treatments focus on angiogenesis and anti-inflammatory strategies.
• Endothelial cells (ECs) play a key role in inflammation and angiogenesis but are not targeted for MI treatment.

Purpose of the Study:

• To develop and evaluate a novel nonviral nucleic acid delivery system for MI treatment.
• To target endothelial cells (ECs) for enhanced therapeutic outcomes in MI.
• To investigate the efficacy of codelivering siR-ICAM1 and pCXCL12 for MI treatment.

Main Methods:

• Development of a specific polycation (CPC) for EC-specific delivery.
• Codelivery of siR-ICAM1 and pCXCL12 using the CPC system.
• Assessment of cardiac function, inflammation, and angiogenesis in MI models.

Main Results:

• Combination therapy significantly improved cardiac systolic function compared to single nucleic acid treatments.
• CPC-based codelivery demonstrated potent anti-inflammatory effects.
• Enhanced angiogenesis was observed in animals treated with the combination therapy.

Conclusions:

• CPC-based combined gene delivery systems show significant promise for treating MI.
• This approach offers a programmed strategy for developing codelivery systems for EC-related diseases.
• Targeting ECs with combined gene therapy represents a viable therapeutic avenue for cardiovascular diseases.